21
Oct
2009
Posted in I - Series C, Q - 3Q09, R - SOUTH EAST, X - Diabetes, X - Opthalmology, XX - GA
Almeria Sciences (Atlanta, GA) a clinical-stage biopharma company focused on ophthalmic disease and treatment of diabetic macular edema, closed a $5M Series C, bringing the total round to $35. Participants have included Polaris Venture Partners, Intersouth Partners, Venrock Associates, Domain Associates and Scale Venture Partners.
22
Jul
2009
22
Jun
2009
15
Jun
2009
Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Alzheimer's, X - Dementia, X - Diabetes, X - Imaging, X - Parkinson's, XX - PA
Avid Radiopharmaceuticals (Philadelphia, PA) a development-stage company focused on molecular imaging compounds for diagnostic and detection use in Alzheimer’s, dementia, Parkinson’s and diabetes, closed a $24.5M Series D financing. Participants include Alta Partners, AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group and BioAdvance.
09
Jun
2009
09
Jun
2009
27
May
2009
Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity, XX - MA
Elixir Pharmaceuticals (Cambridge, MA) a late-stage pharmaceutical company focused on the treatment of metabolic diseases such as diabetes and obesity, closed a $12M Series D financing. Participants include MPM Capital, Arch Venture Partners, Oxford Bioscience Partners, Omega Funds and Physic Ventures.
01
Dec
2008
Posted in I - Series A, Q - 3Q08, R - NORTH EAST, X - Alzheimer's, X - Diabetes
ProteoStasis Therapeutics (Cambridge, MA) developing therapies to treat multiple genetic and degenerative disorders associated with protein homeostasis deficiencies, closed a $45M Series A financing. Participants include HealthCare Ventures, Fidelity Biosciences, New Enterprise Associates, Novartis Option Fund and Genzyme Ventures.
01
Dec
2008
Posted in I - Series C, Q - 3Q08, R - WEST, X - Diabetes, X - Metabolism
InteKrin Therapeutics (Los Altos, CA) clinical-stage biopharmaceutical company focused on the development of products for diabetes, metabolism and obesity, closed a $20M Series C financing. Participants include Skyline Ventures, Sofinnova Ventures, OrbiMed Advisors, , Sears Capital Management and Vivo Ventures.
01
Dec
2008